Site 'Tertiary' Navigation:

Page 'Breadcrumb' Navigation:

Press Releases

 
Press Releases
  Date Title and Summary View
Nov 2, 2010
Lipocine Inc. announced today that it has been awarded four cash grants totaling approximately $978,000 under the U.S. Government’s Qualifying Therapeutic Discovery Project (“QTDP”) program. The QTDP program was part of the Patient Protection and Affordable Care Act signed into la...
Jan 28, 2011
Lipocine Inc. Salt Lake City, Utah, January 28, 2011 (www.lipocine.com) announced today that in addition to its issued patents involving oral testosterone, it has recently filed two new patent applications in support of its oral testosterone product for hypogonadism, also known as low testosterone (low T)...
Jul 6, 2011
Salt Lake City, Utah, July 6, 2011 Lipocine announces that Dr. William Higuchi, Lipocine co-founder and Chairman of the Board, was awarded the 'Order of The Rising Sun' by the Japanese Government for "contribution to the development of Japanese pharmaceutics and pharmaceutical chemistry, as well as to the improvement of social status of Japane...
Dec 5, 2012
(Salt Lake City, December 5, 2012) - Lipocine Inc. (www.lipocine.com) announced today that the Company recently met with FDA and received guidance and go ahead for the Company's pivotal Phase III study for its oral testosterone replacement therapy (LPCN 1021). Lipocine presented the results of its Phase II trials to FDA that indic...
Apr 5, 2013
(Salt Lake City, April 5, 2013) - Lipocine Inc. (www.lipocine.com, a biopharmaceutical company focused on developing innovative oral hormone therapies for men's and women's health, today announced favorable Phase I results for LPCN 1111. LPCN 1111, a novel prodrug of testosterone, uses the Company's proprietary Lipâ€&...
May 7, 2013
Press Release: LifeSci Advisors (NEW YORK, NY--Marketwired - May 7, 2013) - LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of Lipocine Inc., a private biotechnology focused on becoming the leader in sec...
Jul 26, 2013
SALT LAKE CITY (BUSINESS WIRE - July 26, 2013) Lipocine, Inc. (OTCBB:MBARD), a specialty pharmaceutical company, announced today that it has entered into securities purchase agreements with gross proceeds of $38.0 million for the issuance and sale of approximately 6.3 million shares of its common stock at $6.00 per share to inst...
Jul 31, 2013
SALT LAKE CITY (BUSINESS WIRE - July 31, 2013) Lipocine, Inc. (OTCBB:MBARD), a specialty pharmaceutical company, announced today that it has closed its previously announced private placement with institutional investors. In the private placement, Lipocine issued and sold approximately 6.3 million shares of its common stock at $...
Aug 22, 2013
SALT LAKE CITY (BUSINESS WIRE - August 22, 2013) Lipocine Inc.(OTCQB⁄OTCBB:LPCN), a specialty pharmaceutical company, announced today that it has changed its trading symbol from OTCBB:MBARD to OTCQB⁄OTCBB:LPCN. On July 24, 2013, Lipocine successfully completed a reverse merger with Marathon Bar Corp. The combined company is focused sole...
Sep 16, 2013
SALT LAKE CITY (BUSINESS WIRE - September 16, 2013) Lipocine Inc. ("Lipocine") (OTCQB⁄OTCBB:LPCN), a specialty pharmaceutical company, announced today that Morgan Brown has joined the Company as Executive Vice President and Chief Financial Officer ("CFO"). Mr. Brown has more than 20 years of financial and accounting experience, including over...
Page:
1
... NextLast
= add release to Briefcase